The product may be used to treat a condition that the American Academy of Ophthalmology says affects around 20 million ...
The spokesperson added: “Allergan wants its patents to be enforced against infringers, (makers of generic eye drops) but in federal court, not in the IPR proceedings.” The tribe runs a large ...
But with Novartis failing to convince European regulators about the merits of Xiidra last year, and Allergan's ... a phase 3 trial for eye drops containing tivanisiran, in dry eye disease associat ...